论文部分内容阅读
为了确定复发和难治性AML 治疗中Ara-C 的最佳剂量,进行了多中心随机对照研究.病人均符合FAB 标准,复发或对标准第一线方案耐药。方案:Ara-C,第1、2、8、9天,q12h.米妥蒽醌,第3、4、10、11天,剂量均为10ms/m~2/d.Ara-c 每次剂量根据年龄调整如下:随机将<60岁者分为3g/m~2(大剂量)
In order to determine the optimal dose of Ara-C for relapsed and refractory AML, a multicenter randomized controlled study was performed in which patients were all eligible for FAB and relapsed or resistant to standard first-line regimens. Schedule: Ara-C, 1, 2, 8, 9 days, q12h. Mantanthrene, the first 3,4,10,11 days, the dose was 10ms / m ~ 2 / dAra-c per dose According to the age adjustment as follows: Randomly <60 years old were divided into 3g / m ~ 2 (high dose)